Background Clostridium difficile is the most common cause of infectious diarrhea in
hospitalized patients. Recurrences are common after antibiotic therapy. Actoxumab and …

The selection of a novel weekly dalbavancin dosage regimen was based on pharmacokinetic
and pharmacodynamic data from humans and an animal model of infection. The results …

Dalbavancin, a novel glycopeptide with a long elimination half-life (∼9–12 days), was
compared to standard antimicrobial therapy for skin and soft-tissue infections (SSTIs). In a …

Fifty-two healthy adult male and female volunteers were enrolled in this double-blind study
to determine the maximum tolerated dose, characterize the pharmacokinetics, and obtain …

Background Bezlotoxumab is a human monoclonal antibody against Clostridium difficile toxin
B indicated to prevent C. difficile infection (CDI) recurrence (rCDI) in adults at high risk for …

Background. Although newer studies have evaluated risk factors for recurrent Clostridium
difficile infection (CDI), the vast majority did not measure important biomarkers such as …

Background Clostridium difficile infection (CDI) is the most commonly recognized cause of
recurrent diarrhea. Bezlotoxumab, administered concurrently with antibiotics directed against …

Background Carbapenem-resistant Enterobacterales species and multidrug-resistant
Pseudomonas aeruginosa are global health threats. Cefepime–taniborbactam is an investigational …

Sparfloxacin is a broad-spectrum oral fluoroquinolone antimicrobial agent with a long elimination
half-life (t 1 2 ). Concurrent treatment with antacids has demonstrated a reduction in the …

… Mary Beth Dorr … After the quality-control process, high-quality data with an average of 686
Mb were generated, which has a coverage of 170-fold across the whole genome (~ 4 Mb). …